BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: May 18, 2009
Last updated: May 6, 2014
Last verified: May 2014

The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.

Condition Intervention Phase
Colorectal Neoplasms
Drug: BIBF 1120
Drug: mFolfox
Drug: Bevacizumab
Drug: mFolfox 6
Drug: bevacizumab
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • The primary endpoint of the phase II part is the 9 month PFS rate in BIBF 1120 combined with mFolfox6 in comparison to bevacizumab combined with mFolfox6. [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy of BIBF1120 based on OS, PFS, Overall response rate, resection rate and tumour shrinkage [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Appropriate dose of BIBF 1120 in the first 12 to 18 patients when combined with mFolfox6 [ Time Frame: 2 weeks (cycle duration for DLT determination) ] [ Designated as safety issue: No ]
  • Safety assessed by the evaluation of the incidence and intensity of adverse events with grading according to the US NCI Common Terminology Criteria for Adverse Events (CTCAE version 3.0) [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
  • Pharmacokinetics characteristics of BIBF 1120, 5-FU and oxaliplatin [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
  • Quality of life evaluation by the standardised questionnaires European Organization for Research and Treatment of Cancer Quality of Life Questionnaire ( EORTC-QLQ-C30) and Colorectal Cancer-Specific Quality of Life Questionnaire (EORTC-QLQ-CR38) [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]
  • Biomarkers analysis including Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Platelet- Derived Growth Factor (PDGF) plasma levels, Genetic variation, oncogene profile) [ Time Frame: up to 1 year ] [ Designated as safety issue: No ]

Enrollment: 128
Study Start Date: May 2009
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBF 1120 + mFolfox6
BIBF1120 medium dose twice daily
Drug: BIBF 1120
BIBF 1120 100 and 150 mg capsules
Drug: mFolfox 6
IV standard chemotherapy
Drug: bevacizumab
100 mg/4 ml solution
Active Comparator: Bevacizumab + mFolfox6
Bevacizumab 5mg/kg once daily every other week
Drug: BIBF 1120
BIBF 1120 100 and 150 mg capsules
Drug: mFolfox
standard i.v chemotherapy
Drug: Bevacizumab
100 mg/Kg solution , IV infusion


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Age >= 18 years
  2. Histologically proven colorectal adenocarcinoma
  3. No previous oxaliplatin based chemotherapy is allowed unless disease free survival after the end of chemotherapy > = 12 months
  4. No previous therapy with VEGFR or EGFR inhibitors
  5. No prior systemic therapy for metastatic CRC
  6. No previous adjuvant therapy with fluoropyrimidines is allowed unless disease free survival after the end of chemotherapy > 6 months
  7. ECOG performance status < = 2
  8. Adequate hepatic, renal and bone marrow functions:
  9. No uncontrolled hypertension
  10. Signed and dated written informed consent prior to admission to the study

Exclusion criteria:

  1. Treatment with any investigational drug within 28 days of trial onset.
  2. History of other malignancies in the last 5 years, in particular those that could affect compliance with the protocol or interpretation of results.
  3. Serious concomitant disease, especially those affecting compliance with trial requirements or which are considered relevant for the evaluation of the efficacy or safety of the trial drug,
  4. Major injuries and/or surgery or bone fracture within 4 weeks of trial inclusion, or planned surgical procedures during the trial period.
  5. Significant cardiovascular diseases
  6. History of severe haemorrhagic or thromboembolic event in the past 12 months. Known inherited predisposition to bleeding or to thrombosis.
  7. Patient with brain metastases that are symptomatic and/or require therapy.
  8. Pregnancy or breast-feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00904839

  Show 47 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim Identifier: NCT00904839     History of Changes
Other Study ID Numbers: 1199.51, 2008-005364-14
Study First Received: May 18, 2009
Last Updated: May 6, 2014
Health Authority: Belgium: Federal Agency for Medicinal and Health Products
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: Ethics Committee
Spain: Spanish Agency of Medicines
United States: Food and Drug Administration

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 16, 2014